VAL.L
ValiRx PLC
Price:  
0.60 
GBP
Volume:  
4,955,926.00
United Kingdom | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

VAL.L WACC - Weighted Average Cost of Capital

The WACC of ValiRx PLC (VAL.L) is 6.7%.

The Cost of Equity of ValiRx PLC (VAL.L) is 6.75%.
The Cost of Debt of ValiRx PLC (VAL.L) is 6.35%.

Range Selected
Cost of equity 6.00% - 7.50% 6.75%
Tax rate 6.80% - 7.50% 7.15%
Cost of debt 5.70% - 7.00% 6.35%
WACC 6.0% - 7.5% 6.7%
WACC

VAL.L WACC calculation

Category Low High
Long-term bond rate 4.0% 4.5%
Equity market risk premium 6.0% 7.0%
Adjusted beta 0.33 0.36
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.00% 7.50%
Tax rate 6.80% 7.50%
Debt/Equity ratio 0.01 0.01
Cost of debt 5.70% 7.00%
After-tax WACC 6.0% 7.5%
Selected WACC 6.7%

VAL.L's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for VAL.L:

cost_of_equity (6.75%) = risk_free_rate (4.25%) + equity_risk_premium (6.50%) * adjusted_beta (0.33) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.